When combined with seribantumab, the EGFR targeted therapies gefitinib, erlotinib and cetuximab have shown enhanced and more sustained activity in preclinical models of NSCLC, pancreatic ductal adenocarcinoma and HNSCC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.